Anti PD-1/Anti PDL-1 Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Meta-Analysis of Phase 2/3 Randomized Controlled Trials
<b>Importance:</b> Immune checkpoint inhibitors (ICI) have revolutionized the treatment for gastroesophageal cancers (GEC). It is important to investigate the factors that influence the response to anti-PD-1/PD-L1 ICIs. <b>Objective:</b> To assess the benefits of PD-1/PD-L1 I...
Main Authors: | Kanak Parmar, Sai Subramanyam, Kristopher Attwood, Duke Appiah, Christos Fountzilas, Sarbajit Mukherjee |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/9/1953 |
Similar Items
-
Perioperative treatment and biomarker analysis of LP002, an anti‐PD‐L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer
by: Jia‐lin Tang, et al.
Published: (2023-03-01) -
The Multidisciplinary Approach and Surgical Management of GE Junction Adenocarcinoma
by: Meher Oberoi, et al.
Published: (2024-01-01) -
Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Cancers—A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference
by: Karen Mulder, et al.
Published: (2022-04-01) -
Multicenter analysis on the value of standard (chemo)radiotherapy in elderly patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junction
by: Tilman Bostel, et al.
Published: (2024-03-01) -
Global retrospective analysis of clinician- and patient-reported clinical characteristics and humanistic burden of patients with gastroesophageal cancers on first-line treatment
by: Hong Xiao, et al.
Published: (2023-02-01)